Skip to main content
GoodMoatv1.3
Sign in
GILD logo

GILD

CompareEarnings: May 31, 2026

Gilead Sciences Inc

Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - General

For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead researchers have developed 13 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly. Our advances in medical research have helped to transform HIV into a treatable, preventable, chronic condition for millions of people. Gilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world. Through partnerships, collaborations and charitable giving, the company also aims to improve education, expand access and address barriers to care, with the goal of ending the HIV epidemic for everyone, everywhere. Gilead has been recognized as one of the leading philanthropic funders of HIV-related programs in a report released by Funders Concerned About AIDS. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Did you know?

Price sits at 65% of its 52-week range.

Current Price

$133.64

+0.56%

GoodMoat Value

$120.02

10.2% overvalued
Profile
Valuation (TTM)
Market Cap$165.80B
P/E19.48
EV$187.70B
P/B7.30
Shares Out1.24B
P/Sales5.63
Revenue$29.44B
EV/EBITDA13.48

Gilead Sciences Inc (GILD) Company Profile

GoodMoat Analysis

Based on data as of March 26, 2026

Gilead Sciences is a large, profitable biopharmaceutical company with a strong portfolio of antiviral and oncology drugs. While it possesses a moderate moat through patents and regulatory barriers, its low revenue growth and high debt present key risks for value investors. The current GoodMoat target price suggests the stock may be overvalued relative to its intrinsic value.

Read full analysis
Gilead Sciences discovers, develops, and commercializes medicines, primarily in virology (HIV, Hepatitis, COVID-19) and oncology. Its customers are healthcare systems, pharmacies, and patients worldwide. Its primary moat, as per Section 1 of the framework, stems from regulatory barriers and technology leadership. It holds patents on blockbuster drugs like Biktarvy for HIV, granting temporary monopolies. However, its moat score is likely moderate; while it meets criteria like proprietary technology (patents) and niche dominance in HIV, it faces high disruption risk from generic competition when patents expire, and its pricing power is increasingly challenged by healthcare payers. Key risks from Section 5 include competitive erosion as key patents lapse and high customer concentration risk, as a significant portion of revenue depends on government healthcare programs. A value investor might be interested in its high profitability (37.5% ROE, 34% operating margin) and solid free cash flow yield of 5.5%. However, caution is warranted due to its modest 4.7% revenue growth, which is below the double-digit threshold for quality growth, and a debt-heavy balance sheet with a Debt/Equity ratio of 1.1. The GoodMoat target price of $120.02, below the current $138.26, indicates a valuation assessment that is unfavourable, suggesting a lack of margin of safety at the current price. Analysis based on data as of 2024-05-15.

GILD Company Information

For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research.

Gilead researchers have developed 13 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly.

Our advances in medical research have helped to transform HIV into a treatable, preventable, chronic condition for millions of people.

Gilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world.

Through partnerships, collaborations and charitable giving, the company also aims to improve education, expand access and address barriers to care, with the goal of ending the HIV epidemic for everyone, everywhere.

Gilead has been recognized as one of the leading philanthropic funders of HIV-related programs in a report released by Funders Concerned About AIDS. About Gilead Sciences Gilead Sciences, Inc.

is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. Gilead Sciences, Inc.

is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.

The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation.

Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Sector

Healthcare

Industry

Drug Manufacturers - General

Exchange

NASDAQ

Country

California, USA

GILD Key Officers

Key officers data coming soon

GILD Company Profile

Gilead Sciences Inc (GILD) is a Healthcare company in the Drug Manufacturers - General industry. It trades on NASDAQ. The company is based in California, USA.

For more than 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead researchers have developed 13 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly. Our advances in medical research have helped to transform HIV into a treatable, preventable, chronic condition for millions of people. Gilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world. Through partnerships, collaborations and charitable giving, the company also aims to improve education, expand access and address barriers to care, with the goal of ending the HIV epidemic for everyone, everywhere. Gilead has been recognized as one of the leading philanthropic funders of HIV-related programs in a report released by Funders Concerned About AIDS. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Market cap is $165.80B. There are 1240.7M shares outstanding. Dividend yield is 2.41%.

See the full Gilead Sciences Inc profile on GoodMoat. It covers key officers, financial metrics, and sector details. You can also use GoodMoat's DCF calculator, fair value models, and quality score to help decide if GILD is a good investment.